Nicholas Investment Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Nicholas Investment Partners’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-149,425	Closed	-$9.93M	–	221
2021 Q3	$9.93M	Sell	149,425 -75,451	-34%	-$5.38M	0.72%	56
2021 Q2	$17.5M	Buy	224,876 +6,029	+3%	+$446K	1.1%	31
2021 Q1	$20.7M	Buy	218,847 +35,171	+19%	+$4.18M	1.44%	14
2020 Q4	$22.4M	Buy	183,676 +319	+0.2%	+$34.9K	1.73%	12
2020 Q3	$16M	Buy	183,357 +151,978	+484%	+$10.6M	1.73%	13
2020 Q2	$2.03M	Sell	31,379 -44,108	-58%	-$2.54M	0.41%	94
2020 Q1	$3.37M	Sell	75,487 -4,955	-6%	-$263K	0.66%	59
2019 Q4	$5.01M	Sell	80,442 -26,169	-25%	-$1.25M	0.52%	53
2019 Q3	$4.01M	Sell	106,611 -279	-0.3%	-$12.1K	0.34%	117
2019 Q2	$4.35M	Buy	+106,890	New	+$3.81M	0.4%	92

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Nicholas Investment Partners's TPTX Position: Q4 2021 in Review

Nicholas Investment Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 149,425 shares — an estimated $9.93M sold.

Nicholas Investment Partners first reported a position in TPTX in Q2 2019 and held it in 10 quarters. The position peaked at $22.4M in Q4 2020. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Nicholas Investment Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Nicholas Investment Partners sold 149,425 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $9.93M.
Nicholas Investment Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Nicholas Investment Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $22.4M in Q4 2020.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Nicholas Investment Partners's 13F filing for Q4 2021, filed 14 Feb 2022.